Inogen, Inc (NASDAQ:INGN - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $6.64 and traded as high as $6.73. Inogen shares last traded at $6.35, with a volume of 175,607 shares.
Analyst Ratings Changes
Several equities research analysts have recently commented on the stock. B. Riley assumed coverage on shares of Inogen in a research report on Monday, June 16th. They set a "buy" rating and a $14.00 price target for the company. Needham & Company LLC upgraded shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective for the company in a report on Thursday, May 22nd. Finally, Stifel Nicolaus decreased their price objective on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a report on Thursday, May 8th.
Read Our Latest Stock Report on INGN
Inogen Price Performance
The stock's 50-day moving average price is $6.64 and its 200 day moving average price is $7.92. The firm has a market cap of $170.48 million, a P/E ratio of -5.51 and a beta of 1.66.
Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.27. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. As a group, analysts forecast that Inogen, Inc will post -1.73 EPS for the current fiscal year.
Hedge Funds Weigh In On Inogen
Several large investors have recently modified their holdings of the stock. Meeder Asset Management Inc. acquired a new position in shares of Inogen in the fourth quarter valued at about $56,000. Integrated Wealth Concepts LLC acquired a new position in shares of Inogen in the first quarter valued at about $85,000. Algert Global LLC acquired a new position in shares of Inogen in the first quarter valued at about $89,000. Integrated Quantitative Investments LLC acquired a new stake in Inogen during the fourth quarter worth about $92,000. Finally, Intech Investment Management LLC acquired a new stake in Inogen during the fourth quarter worth about $94,000. 89.94% of the stock is owned by institutional investors.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access